Session Type: Poster Session B
Session Time: 9:00AM-10:30AM
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is an ANCA-associated vasculitides characterized by asthma, blood and tissue eosinophilia and systemic manifestations. Glucocorticosteroids (GCs)-dependent asthma and/or disabling ear, nose and throat (ENT) symptoms may persist in half of the patients. Mepolizumab represent an important strategy in these situations. Nevertheless, some patients may show poor or dissociated response between asthma and ENT involvement, requiring alternative options. Dupilumab, a monoclonal antibody directed against the IL-4/IL-13 receptor, has been approved for the treatment of eosinophilic asthma and chronic rhinosinusitis with nasal polyposis, raising the question of its efficacy and its tolerance in EGPA. We aimed to describe the safety and efficacy of the off-label use of dupilumab to treat relapsing and/or refractory EGPA.
Methods: European multicenter retrospective study including patients with EGPA fulfilling 2022 ACR/EULAR classification criteria and treated with dupilumab. We collected safety and efficacy data. Response was defined as complete by BVAS=0 and prednisone dose ≤4 mg/day, and partial by BVAS=0 and prednisone dose >4 mg/d
Results: Thirty-four patients were included, median age of 52.5 years (IQR, 45.3-57.0) and 23 were women (68%). Dupilumab was initiated for disabling ENT manifestations in 28 (82%) cases, poorly controlled asthma in 21 (62%) and/or GCs-dependency in 23 (68%). Dupilumab was associated with azathioprine in 2, methotrexate in 1 and mycophenolate in 1.
Median follow-up after dupilumab initiation was 7.7 (4.4-13.1) months. Nineteen (56%) patients reported adverse events (AE). Main AE were mild-to-moderate and included headache (n=2), injection-site reaction (n=2) and myalgia (n=2). Three AE were severe and led to dupilumab discontinuation: anaphylactic shock (n=2) and headache (n=1). Three additional patients discontinued dupilumab due to symptomatic hypereosinophilia (n=2) and exacerbation of psoriasis (n=1). Dupilumab-induced eosinophilia was reported in 17 patients (50%), with a peak eosinophil count of 1500/mm3 (1200-2900) after 13 weeks (4-13) of dupilumab. This transient hypereosinophilia remained asymptomatic in most cases. No death was reported.
Sixteen patients (47%) achieved a complete response and 16 (47%) a partial response. Median BVAS was 3 (0.5-4) at dupilumab initiation and dropped to 0 (0-0) at 6 months. Baseline prednisone dose was 10 mg/d (5-15) and decreased to 5 (0.6-5) at 6 months. Efficacy could not be assessed in two cases due to early discontinuation of dupilumab.
Finally, 6 (18%) patients presented a EGPA flare leading to dupilumab discontinuation in 4 cases, including asthma exacerbation in 3 cases, systemic vasculitis manifestations in 2 and inflammatory arthritis in one.
Conclusion: Dupilumab was associated with frequent mild-to-moderate AE, and induced-eosinophilia in half of patients, most frequently transient and asymptomatic. A clinical benefit was noted in most patients. Dupilumab could therefore constitute an alternative therapeutic option in selected patients refractory to anti-IL-5 drugs.
To cite this abstract in AMA style:Molina B, Urban M, Padoan R, Novikov P, Taillé C, Caminati M, Christides C, schleinitz n, Moi L, Cottin V, godeau b, Bouillet L, Fraticelli P, Knight A, Schroeder J, Marchand-Adam S, Gil H, Gelain E, Emmi G, Terrier B. Safety and Efficacy of Dupilumab in Patients with Relapsing and/or Refractory Eosinophilic Granulomatosis with Polyangiitis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/safety-and-efficacy-of-dupilumab-in-patients-with-relapsing-and-or-refractory-eosinophilic-granulomatosis-with-polyangiitis/. Accessed January 30, 2023.
« Back to ACR Convergence 2022
ACR Meeting Abstracts - https://acrabstracts.org/abstract/safety-and-efficacy-of-dupilumab-in-patients-with-relapsing-and-or-refractory-eosinophilic-granulomatosis-with-polyangiitis/